Efficacy of SP and XP for HER2-negative unresectable advanced recurrent gastric cancer varies by histologic type
2022
進行胃癌一次治療におけるSP対XPの無作為化試験のメタ解析
Efficacy of SP and XP for HER2-negative unresectable advanced recurrent gastric cancer varies by histologic type
TRESBIEN (OGSG 2101): encorafenib, binimetinib and cetuximab for early recurrent stage II/III BRAF V600E-mutated colorectal cancer
Histology Classification Highlights Differences in Efficacy of S-1 versus Capecitabine, in Combination with Cisplatin, for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer with Measurable Disease
TRESBIEN (OGSG 2101) Encorafenib, binimetinib and cetuximab for early recurrent Stage II/III BRAF V600E-mutated CRC
Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy OGSG1201
Neoadjuvant docetaxel, oxaliplatin and S‑1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902) protocol of a multi‑center, phase II study
The Phase II Study of Panitumumab in Chemotherapy- Naïve Frail or Elderly Patients with RAS Wild-type Colorectal Cancer OGSG 1602 Final Results
Protocol of OGSG 1901 a phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S − 1 therapy